Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockGlobeNewsWire · 4 days ago
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire · 5 days ago
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP TranscriptSeeking Alpha · 5 days ago
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal StudyBenzinga · 5 days ago
Disc Medicine stock soars: take profit or buy into strength?Invezz · 5 days ago
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP TreatmentGuruFocus · 5 days agoBased in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$1.71 | -$1.54 | Beat |
| May 5, 2026 | -$1.55 | -$1.65 | Miss |
| Feb 26, 2026 | -$1.69 | -$1.62 | Beat |
| Nov 6, 2025 | -$1.48 | -$1.77 | Miss |
| Aug 7, 2025 | -$1.17 | -$1.58 | Miss |
| May 7, 2025 | -$0.99 | -$1.02 | Miss |